国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (12): 881-885.doi: 10.3760/cma.j.issn.1673422X.2016.12.001

• 论著 •    下一篇

DC-CIK联合化疗对乳腺癌患者Treg细胞表达

张志胜   

  1. 江苏省泰州市第二人民医院肿瘤科
  • 出版日期:2016-12-08 发布日期:2016-11-02

Effect of DCCIK combined with chemotherapy on Treg cell expression and prognosis in patients with breast cancer

ZHANG  Zhi-Sheng   

  1. Department of Oncology, Second People′s Hospital of Taizhou, Jiangsu Province, Taizhou 225300, China
  • Online:2016-12-08 Published:2016-11-02

PDF

1095

摘要： 目的探讨树突状细胞（DC）与细胞因子诱导的杀伤细胞（CIK）联合化疗对乳腺癌患者Treg细胞表达和预后的影响。方法试验组42例患者术后接受DCCIK细胞联合化疗，对照组38例患者仅接受单纯化疗，比较两组患者治疗后外周血中Treg细胞表达量，比较两组近期疗效、无进展生存期（PFS）、总生存期（OS）以及治疗后的生命质量。结果治疗后1周试验组患者外周血中Treg细胞表达量明显低于对照组［（11.37±1.10）%∶（14.25±0.95）%］，治疗后2周试验组患者外周血中Treg细胞表达量明显低于对照组［（7.94±1.12）%∶（9.14±1.21）%］，差异均有统计学意义（t=12.470，P=0.000；t=4.606，P=0.000）。试验组临床有效率与对照组比较（47.62%∶44.74%），差异无统计学意义（χ2=0.07，P=0.80）；试验组疾病控制率明显高于对照组（80.95%∶60.53%），差异有统计学意义（χ2=4.06，P=0.04）。试验组患者的PFS［（7.50±1.45）个月∶（5.50±1.52）个月］和OS［（13.50±3.20）个月∶（11.50±3.25）个月］均明显长于对照组，差异均有统计学意义（t=6.021，P=0.000；t=2.771，P=0.007）。治疗后试验组患者在躯体功能（72.85±12.01∶57.42±13.07）、情绪功能（68.45±9.97∶44.79±9.15）、认知功能（67.54±9.95∶62.37±10.34）、社会功能（65.72±12.17∶49.37±8.45）和总体生命质量（71.43±11.50∶59.48±12.45）方面的评分均明显高于对照组，差异均有统计学意义（t=5.503，P=0.000；t=11.020，P=0.000；t=2.278，P=0.025；t=7.032，P=0.000；t=4.463，P=0.000）。结论DCCIK联合化疗能够显著降低乳腺癌患者外周血中Treg细胞的表达，改善免疫抑制情况，同时提高疗效，延长PFS，提高患者的生命质量。

关键词: 乳腺肿瘤, 树突细胞, 杀伤细胞, Treg细胞, 无进展生存期

Abstract: ObjectiveTo study the effect of dendritic cells (DCs) and cytokineinduced killer cells (CIKs) combined with chemotherapy on Treg cell expression and prognosis of patients with breast cancer. MethodsPatients in the test group (n=42) were treated with DCCIK therapy combined with chemotherapy, and patients in the control group (n=38) were treated with chemotherapy. The expressions of Treg cells in peripheral blood, the shortterm efficacy, progressionfree survival (PFS), overall survival (OS) and quality of life after treatment were compared between the two groups. ResultsIn the test group, the expressions of Treg cells in peripheral blood after 1 week treatment were significantly lower than those in the control group ［(11.37±1.10)% vs. (14.25±0.95)%］, and the expressions of Treg cells in peripheral blood after 2 weeks treatment were significantly lower than those in the control group ［(7.94±1.12)% vs. (9.14±1.21)%］, with significant differences (t=12.470, P=0.000; t=4.606, P=0.000). The test group and the control group had the similar clinical efficacy rate (47.62% vs. 44.74%), with no significant difference (χ2=0.07, P=0.80). The disease control rate in the test group was significantly higher than that in the control group (80.95% vs. 60.53%), with a significant difference (χ2=4.06, P=0.04). The PFS ［(7.50±1.45) months vs. (5.50±1.52) months］ and OS ［(13.50±3.20) months vs. (11.50±3.25) months］ of patients in the test group were significantly higher than those in the control group, with significant differences (t=6.021, P=0.000; t=2.771, P=0.007). After treatment, the scores of the test group patients in physical function (72.85±12.01 vs. 57.42±13.07), emotional function (68.45±9.97 vs. 44.79±9.15), cognitive function (67.54±9.95 vs. 62.37±10.34), social function (65.72±12.17 vs. 49.37±8.45) and overall quality of life (71.43±11.50 vs. 59.48±12.45) were significantly higher than those in the control group, with significant differences (t=5.503, P=0.000; t=11.020, P=0.000; t=2.278, P=0.025; t=7.032, P=0.000; t=4.463, P=0.000). ConclusionDCCIK combined with chemotherapy can significantly reduce the expressions of Treg cells in peripheral blood, improve immune suppression, while increasing the curative efficacy, prolonging PFS and improving the quality of life of patients.

Key words: reast neoplasms, Dendritic cells, Killer cells, Treg cells, Progressionfree survival